Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 31 (4), 288-300

Etodolac. A Preliminary Review of Its Pharmacodynamic Activity and Therapeutic Use

Review

Etodolac. A Preliminary Review of Its Pharmacodynamic Activity and Therapeutic Use

S Lynch et al. Drugs.

Abstract

Etodolac is a new non-steroidal agent (NSAID) with anti-inflammatory and analgesic activity. It has been studied in rheumatoid arthritis, osteoarthritis, and pain resulting from minor surgery. In the latter setting, etodolac is at least as effective as aspirin in terms of overall pain relief, and the duration of analgesic effect of a dose of 200 to 400mg is longer than that of aspirin. In rheumatoid arthritis, etodolac, administered twice daily, appears comparable in efficacy to moderate doses of aspirin (3 to 4g daily), but is better tolerated. To date, etodolac has not been compared clinically with analgesics other than aspirin and sulindac. As with other non-steroidal agents, gastrointestinal complaints are the most frequently reported side effects, but the incidence of most gastrointestinal effects was only slightly higher than with placebo. Thus, from studies in small numbers of patients etodolac appears at least as effective as aspirin and better tolerated. The relatively low incidence of gastrointestinal side effects in these studies awaits confirmation in well designed comparisons with widely used NSAIDs.

Similar articles

See all similar articles

Cited by 7 PubMed Central articles

See all "Cited by" articles

References

    1. J Clin Pharmacol. 1984 May-Jun;24(5-6):240-6 - PubMed
    1. J Oral Maxillofac Surg. 1984 Jun;42(6):362-6 - PubMed
    1. J Pharmacol Exp Ther. 1982 Feb;220(2):417-26 - PubMed
    1. Agents Actions. 1984 Oct;15(3-4):403-12 - PubMed
    1. Drug Metab Rev. 1981;12(2):339-62 - PubMed

MeSH terms

LinkOut - more resources

Feedback